Leukemia Research Foundation News

Researcher Describes Breakthrough Drug That May Prevent Post-transplant Relapse

Nearly half of acute myeloid leukemia patients relapse after a bone marrow transplant. Raffaella Di Micco, PhD, and Luca Vago, MD, PhD, from Ospedale San Raffaele in Milan, Italy, have uncovered why and are currently exploring the use of an experimental drug that shows promising results in the lab.

The next step is to begin clinical trials to test the treatment in AML patients, potentially paving the way for the first effective therapy for preventing relapse after transplant.

Watch the video below to learn more about this research from Dr. Di Micco.

This research was funded in part by the Leukemia Research Foundation.

Dr. Di Micco is a group leader of the San Raffaele Telethon Institute for Gene Therapy of Milan and a New York Stem Cell Foundation Robertson Investigator. Dr. Vago is an associate professor of Hematology at the Vita-Salute San Raffaele University and group leader of the Division of Immunology, Transplantation and Infectious Diseases of IRCCS Ospedale San Raffaele.


Pre-transplant gut microbiome may influence likelihood of GVHD

New findings may help donor cells survive AML immunotherapy treatment

New solution shows promise for some AML chemo-resistant cells